Effectiveness and safety of photoselective vaporization of the prostate with the 120 W HPS greenlight laser in benign prostatic hyperplasia patients taking oral anticoagulants

Korean Journal of Urology

Volumn 52, Issue 3, 2011, Pages 178-183

  Sohn, Jun Ho ^a   Choi, Yong Sun ^a   Kim, Su Jin ^a   Cho, Hyuk Jin ^a   Hong, Sung Hoo ^a   Lee, Ji Youl ^a   Hwang, Tae Kon ^a   Kim, Sae Woong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Anticoagulants; Laser therapy; Prostatic hyperplasia

Indexed keywords

ANTICOAGULANT AGENT; HEMOGLOBIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; FOLLOW UP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LASER SURGERY; MALE; PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE; POSTVOID RESIDUAL URINE VOLUME; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SAFETY; SURGICAL TECHNIQUE; URINE FLOW RATE;

EID: 79953174631     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2011.52.3.178     Document Type: Article

References (30)

1. Yu X, Elliott SP, Wilt TJ, McBean AM. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol 2008;180:241-5.
2. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol 2006;50:969-79.
3. Fitzpatrick JM, Mebust KW. Minimally invasive and endoscopic management of benign prostatic hyperplasia. In: Walsh CW, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's urology. 8th ed. Philadelphia: WB Saunders; 2004;1402.
4. Westenberg A, Gilling P, Kennett K, Frampton C, Fraundorfer M. Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum long-term followup. J Urol 2004;172:616-9.
5. Gürdal M, Tekin A, Yücebaş EE, Sengör F. Nd: YAG laser ablation plus transurethral resection for large prostates in high-risk patients. Urology 2003;62:914-7.
6. Shingleton WB, Farabaugh P, May W. Three-year follow-up of laser prostatectomy versus transurethral resection of the prostate in men with benign prostatic hyperplasia. Urology 2002;60: 305-8.
7. Horninger W, Unterlechner H, Strasser H, Bartsch G. Transurethral prostatectomy: mortality and morbidity. Prostate 1996;28: 195-200.
8. Uchida T, Ohori M, Soh S, Sato T, Iwamura M, Ao T, et al. Factors influencing morbidity in patients under-going transurethral resection of the prostate. Urology 1999;53:98-105.
9. Doll HA, Black NA, McPherson K, Flood AB, Williams GB, Smith JC. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol 1992;147:1566-73.
10. Hedlund PO. Postoperative venous thrombosis in benign prostatic disease. A study of 316 patients, using the 125I-fibrinogen uptake test. Scand J Urol Nephrol 1975;(27 Suppl):1-100.
11. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-11.
12. Wong C, Araki M, Tonkin JB. High-power potassium-titanylphosphate or lithium triboride laser photoselective vaporization prostatectomy for benign prostatic hyperplasia: a systematic approach. J Endourol 2007;21:1141-4.
13. Chakravarti A, MacDermott S. Transurethral resection of the prostate in the anticoagulated patient. Br J Urol 1998;81:520-2.
14. Tscholl R, Straub W, Zingg E. Electroresection of the prostate in patients treated with heparin. J Urol 1980;124:221-2.
15. Dotan ZA, Mor Y, Leibovitch I, Varon D, Golomb J, Duvdevani M, et al. The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol 2002;168:610-3.
16. Bell CR, Murdock PJ, Pasi KJ, Morgan RJ. Thrombotic risk factors associated with transurethral prostatectomy. BJU Int 1999; 83:984-9.
17. Te AE. The development of laser prostatectomy. BJU Int 2004; 93:262-5.
18. Carter A, Sells H, Speakman M, Ewings P, MacDonagh R, O'Boyle P. A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1-year follow- up. BJU Int 1999;83:254-9.
19. Malek RS, Kuntzman RS, Barrett DM. High power potassiumtitanyl- phosphate laser vaporization prostatectomy. J Urol 2000; 163:1730-3.
20. Alivizatos G, Skolarikos A. Greenlight laser in benign prostatic hyperplasia: turning green into gold. Curr Opin Urol 2008;18: 46-9.
21. Bachmann A, Ruszat R, Wyler S, Reich O, Seifert H, Müller A, et al. Photoselective vaporization of the prostate: the basel experience after 108 procedures. Eur Urol 2005;47:798-804.
22. Sarica K, Alkan E, Lüleci H, Taşci AI. Photoselective vaporization of the enlarged prostate with KTP laser: long-term results in 240 patients. J Endourol 2005;19:1199-202.
23. Ko DW, Jeong BC, Son H. Initial experience with a new 120 W GreenlightTM high-power system for photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia in Korea. Korean J Urol 2009;50:1089-94.
24. Bachmann A, Schürch L, Ruszat R, Wyler SF, Seifert HH, Müller A, et al. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol 2005;48:965-71.
25. Bouchier-Hayes DM, Anderson P, Van Appledorn S, Bugeja P, Costello AJ. KTP laser versus transurethral resection: early results of a randomized trial. J Endourol 2006;20:580-5.
26. Kim HS, Cho MC, Ku JH, Kim SW, Paick JS. The efficacy and safety of photoselective vaporization of the prostate with a potassium- titanyl-phosphate laser for symptomatic benign prostaticThe Safety of Laser PVP under Oral Anticoagulant 183 hyperplasia according to prostate size: 2-year surgical outcomes. Korean J Urol 2010;51:330-6.
27. Malek RS, Kuntzman RS, Barrett DM. Photoselective potassium- titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 2005;174:1344-8.
28. Pfitzenmaier J, Gilfrich C, Pritsch M, Herrmann D, Buse S, Haferkamp A, et al. Vaporization of prostates of > or=80 mL using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates of <80 mL. BJU Int 2008;102:322-7.
29. Sandhu JS, Ng C, Vanderbrink BA, Egan C, Kaplan SA, Te AE. High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology 2004;64:1155-9.
30. Ruszat R, Wyler S, Seifert HH, Reich O, Forster T, Sulser T, et al. Photoselective vaporization of the prostate: subgroup analysis of men with refractory urinary retention. Eur Urol 2006;50:1040-9.